The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study
Background: It has been suggested that an exaggerated immune response to fungi is crucial in the pathogenesis of chronic rhinosinusitis (CRS). Based on this rationale, the use of topical antifungals (amphotericin B) has been advocated. Studies on its clinical effectiveness are, however, contradictor...
Gespeichert in:
| Veröffentlicht in: | The Laryngoscope 2009-02, Vol.119 (2), p.401-408 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 408 |
|---|---|
| container_issue | 2 |
| container_start_page | 401 |
| container_title | The Laryngoscope |
| container_volume | 119 |
| creator | Ebbens, Fenna A. Georgalas, Christos Luiten, Silvia van Drunen, Cornelis M. Badia, Lydia Scadding, Glenis K. Hellings, Peter W. Jorissen, Mark Mullol, Joaquim Cardesin, Alda Bachert, Claus van Zele, Thibaut P. J. Lund, Valerie J. Fokkens, W. J. |
| description | Background:
It has been suggested that an exaggerated immune response to fungi is crucial in the pathogenesis of chronic rhinosinusitis (CRS). Based on this rationale, the use of topical antifungals (amphotericin B) has been advocated. Studies on its clinical effectiveness are, however, contradictory.
Objectives:
To examine the effect of nasal antifungal treatment on secreted mediators in samples of nasal lavage fluid from patients with CRS with or without nasal polyps (NP).
Methods:
Part two of a prospective double‐blind, placebo‐controlled multicenter clinical trial investigating the effect of 13 weeks of treatment with amphotericin B or placebo on the levels of pro‐inflammatory cytokines, chemokines and growth factors (i.e., IL‐1β, IL‐1RA, IL‐2, IL‐2R, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12 (p40/p70 subunits), IL‐13, IL‐15, IL‐17, TNF‐α, IFN‐α, IFN‐γ, G‐CSF, GM‐CSF, MIP‐1α, MIP‐1β, IP‐10, MIG, eotaxin, RANTES, MCP‐1, MCP‐2, MCP‐3, VEGF, EGF, FGF‐basic, HGF, Gro‐α) and albumin via a fluorescent enzyme immunoassay in nasal lavage specimens of CRS patients with or without NP.
Results:
Topical amphotericin B had no significant effect on the level of any of the tested pro‐inflammatory cytokines, chemokines, and growth factors in CRS nasal lavage samples. Treatment with placebo, however, increased the level of MIP‐1α and MIP‐1β, which are mediators involved in wound healing.
Conclusions:
Topical amphotericin B has no significant effect on activation markers of nasal inflammatory cells in chronic rhinosinusitis with or without nasal polyps. Laryngoscope, 2009 |
| doi_str_mv | 10.1002/lary.20064 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66878081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66878081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4314-c49731229e47a524e682658361ef5523206dff450fc4cc969194f6413e2f2f093</originalsourceid><addsrcrecordid>eNp9kU9vFCEYhydGY9fqxQ9guOjBZCr_Z_C23djVZKOJqVFPBBnIogxMgUkdv0S_stRd680LkJfnfX_hoWmeIniGIMSvvErLGYaQ03vNCjGCWioEu9-s6iVpe4a_nDSPcv4OIeoIgw-bEyQQhxTSVXNzuTfAWGt0AdGCEienlQdqnPaxmOS0C-AcxABcsF6NoyoxLWBU6YdJuRbBpIozoWRw7coe6H2KwWmQ9i7E7MKcXXH5NViDcfbF6UqaBJIKQxzdLzMAHUNJ0ft6zGUelsfNA6t8Nk-O-2nz6eLN5eZtu_uwfbdZ71pNCaJ1FR1BGAtDO8UwNbzHnPWEI2MZwwRDPlhLGbSaai24QIJaThEx2GILBTltXhzmTilezSYXObqsjfcqmDhnyXnf9bBHFXx5AHWKOSdj5ZRcff8iEZS3-uWtfvlHf4WfHafO30Yz_EOPvivw_AioXD3bakK7fMdhhIiouZVDB-7aebP8J1Lu1h-__g1vDz0uF_Pzrqd-leQd6Zj8_H4rOTkXW0g2EpHfb-ut_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66878081</pqid></control><display><type>article</type><title>The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ebbens, Fenna A. ; Georgalas, Christos ; Luiten, Silvia ; van Drunen, Cornelis M. ; Badia, Lydia ; Scadding, Glenis K. ; Hellings, Peter W. ; Jorissen, Mark ; Mullol, Joaquim ; Cardesin, Alda ; Bachert, Claus ; van Zele, Thibaut P. J. ; Lund, Valerie J. ; Fokkens, W. J.</creator><creatorcontrib>Ebbens, Fenna A. ; Georgalas, Christos ; Luiten, Silvia ; van Drunen, Cornelis M. ; Badia, Lydia ; Scadding, Glenis K. ; Hellings, Peter W. ; Jorissen, Mark ; Mullol, Joaquim ; Cardesin, Alda ; Bachert, Claus ; van Zele, Thibaut P. J. ; Lund, Valerie J. ; Fokkens, W. J.</creatorcontrib><description>Background:
It has been suggested that an exaggerated immune response to fungi is crucial in the pathogenesis of chronic rhinosinusitis (CRS). Based on this rationale, the use of topical antifungals (amphotericin B) has been advocated. Studies on its clinical effectiveness are, however, contradictory.
Objectives:
To examine the effect of nasal antifungal treatment on secreted mediators in samples of nasal lavage fluid from patients with CRS with or without nasal polyps (NP).
Methods:
Part two of a prospective double‐blind, placebo‐controlled multicenter clinical trial investigating the effect of 13 weeks of treatment with amphotericin B or placebo on the levels of pro‐inflammatory cytokines, chemokines and growth factors (i.e., IL‐1β, IL‐1RA, IL‐2, IL‐2R, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12 (p40/p70 subunits), IL‐13, IL‐15, IL‐17, TNF‐α, IFN‐α, IFN‐γ, G‐CSF, GM‐CSF, MIP‐1α, MIP‐1β, IP‐10, MIG, eotaxin, RANTES, MCP‐1, MCP‐2, MCP‐3, VEGF, EGF, FGF‐basic, HGF, Gro‐α) and albumin via a fluorescent enzyme immunoassay in nasal lavage specimens of CRS patients with or without NP.
Results:
Topical amphotericin B had no significant effect on the level of any of the tested pro‐inflammatory cytokines, chemokines, and growth factors in CRS nasal lavage samples. Treatment with placebo, however, increased the level of MIP‐1α and MIP‐1β, which are mediators involved in wound healing.
Conclusions:
Topical amphotericin B has no significant effect on activation markers of nasal inflammatory cells in chronic rhinosinusitis with or without nasal polyps. Laryngoscope, 2009</description><identifier>ISSN: 0023-852X</identifier><identifier>EISSN: 1531-4995</identifier><identifier>DOI: 10.1002/lary.20064</identifier><identifier>PMID: 19160404</identifier><identifier>CODEN: LARYA8</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Intranasal ; Administration, Topical ; Adult ; amphotericin B ; Amphotericin B - administration & dosage ; Antifungal Agents - administration & dosage ; Biological and medical sciences ; chemokine CCL3 ; chemokine CCL4 ; chemokines ; Chemokines - analysis ; Chi-Square Distribution ; Chronic Disease ; cytokines ; Cytokines - analysis ; Double-Blind Method ; Female ; fungi ; human ; Humans ; Inflammation - drug therapy ; Intercellular Signaling Peptides and Proteins - analysis ; intracellular signalling peptides and proteins ; intranasal administration ; Male ; Medical sciences ; Middle Aged ; Nasal Lavage ; nasal lavage fluid ; nasal polyps ; Nasal Polyps - drug therapy ; Nasal Polyps - microbiology ; Non tumoral diseases ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; Prospective Studies ; prospective study ; Randomized controlled trial ; Rhinitis - drug therapy ; Rhinitis - immunology ; Rhinitis - microbiology ; rhinosinusitis ; Sinusitis - drug therapy ; Sinusitis - immunology ; Sinusitis - microbiology ; Statistics, Nonparametric ; Treatment Outcome ; Tumors ; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><ispartof>The Laryngoscope, 2009-02, Vol.119 (2), p.401-408</ispartof><rights>Copyright © 2009 The American Laryngological, Rhinological, and Otological Society, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4314-c49731229e47a524e682658361ef5523206dff450fc4cc969194f6413e2f2f093</citedby><cites>FETCH-LOGICAL-c4314-c49731229e47a524e682658361ef5523206dff450fc4cc969194f6413e2f2f093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flary.20064$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flary.20064$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21139780$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19160404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebbens, Fenna A.</creatorcontrib><creatorcontrib>Georgalas, Christos</creatorcontrib><creatorcontrib>Luiten, Silvia</creatorcontrib><creatorcontrib>van Drunen, Cornelis M.</creatorcontrib><creatorcontrib>Badia, Lydia</creatorcontrib><creatorcontrib>Scadding, Glenis K.</creatorcontrib><creatorcontrib>Hellings, Peter W.</creatorcontrib><creatorcontrib>Jorissen, Mark</creatorcontrib><creatorcontrib>Mullol, Joaquim</creatorcontrib><creatorcontrib>Cardesin, Alda</creatorcontrib><creatorcontrib>Bachert, Claus</creatorcontrib><creatorcontrib>van Zele, Thibaut P. J.</creatorcontrib><creatorcontrib>Lund, Valerie J.</creatorcontrib><creatorcontrib>Fokkens, W. J.</creatorcontrib><title>The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study</title><title>The Laryngoscope</title><addtitle>The Laryngoscope</addtitle><description>Background:
It has been suggested that an exaggerated immune response to fungi is crucial in the pathogenesis of chronic rhinosinusitis (CRS). Based on this rationale, the use of topical antifungals (amphotericin B) has been advocated. Studies on its clinical effectiveness are, however, contradictory.
Objectives:
To examine the effect of nasal antifungal treatment on secreted mediators in samples of nasal lavage fluid from patients with CRS with or without nasal polyps (NP).
Methods:
Part two of a prospective double‐blind, placebo‐controlled multicenter clinical trial investigating the effect of 13 weeks of treatment with amphotericin B or placebo on the levels of pro‐inflammatory cytokines, chemokines and growth factors (i.e., IL‐1β, IL‐1RA, IL‐2, IL‐2R, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12 (p40/p70 subunits), IL‐13, IL‐15, IL‐17, TNF‐α, IFN‐α, IFN‐γ, G‐CSF, GM‐CSF, MIP‐1α, MIP‐1β, IP‐10, MIG, eotaxin, RANTES, MCP‐1, MCP‐2, MCP‐3, VEGF, EGF, FGF‐basic, HGF, Gro‐α) and albumin via a fluorescent enzyme immunoassay in nasal lavage specimens of CRS patients with or without NP.
Results:
Topical amphotericin B had no significant effect on the level of any of the tested pro‐inflammatory cytokines, chemokines, and growth factors in CRS nasal lavage samples. Treatment with placebo, however, increased the level of MIP‐1α and MIP‐1β, which are mediators involved in wound healing.
Conclusions:
Topical amphotericin B has no significant effect on activation markers of nasal inflammatory cells in chronic rhinosinusitis with or without nasal polyps. Laryngoscope, 2009</description><subject>Administration, Intranasal</subject><subject>Administration, Topical</subject><subject>Adult</subject><subject>amphotericin B</subject><subject>Amphotericin B - administration & dosage</subject><subject>Antifungal Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>chemokine CCL3</subject><subject>chemokine CCL4</subject><subject>chemokines</subject><subject>Chemokines - analysis</subject><subject>Chi-Square Distribution</subject><subject>Chronic Disease</subject><subject>cytokines</subject><subject>Cytokines - analysis</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>fungi</subject><subject>human</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Intercellular Signaling Peptides and Proteins - analysis</subject><subject>intracellular signalling peptides and proteins</subject><subject>intranasal administration</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nasal Lavage</subject><subject>nasal lavage fluid</subject><subject>nasal polyps</subject><subject>Nasal Polyps - drug therapy</subject><subject>Nasal Polyps - microbiology</subject><subject>Non tumoral diseases</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Prospective Studies</subject><subject>prospective study</subject><subject>Randomized controlled trial</subject><subject>Rhinitis - drug therapy</subject><subject>Rhinitis - immunology</subject><subject>Rhinitis - microbiology</subject><subject>rhinosinusitis</subject><subject>Sinusitis - drug therapy</subject><subject>Sinusitis - immunology</subject><subject>Sinusitis - microbiology</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><issn>0023-852X</issn><issn>1531-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9vFCEYhydGY9fqxQ9guOjBZCr_Z_C23djVZKOJqVFPBBnIogxMgUkdv0S_stRd680LkJfnfX_hoWmeIniGIMSvvErLGYaQ03vNCjGCWioEu9-s6iVpe4a_nDSPcv4OIeoIgw-bEyQQhxTSVXNzuTfAWGt0AdGCEienlQdqnPaxmOS0C-AcxABcsF6NoyoxLWBU6YdJuRbBpIozoWRw7coe6H2KwWmQ9i7E7MKcXXH5NViDcfbF6UqaBJIKQxzdLzMAHUNJ0ft6zGUelsfNA6t8Nk-O-2nz6eLN5eZtu_uwfbdZ71pNCaJ1FR1BGAtDO8UwNbzHnPWEI2MZwwRDPlhLGbSaai24QIJaThEx2GILBTltXhzmTilezSYXObqsjfcqmDhnyXnf9bBHFXx5AHWKOSdj5ZRcff8iEZS3-uWtfvlHf4WfHafO30Yz_EOPvivw_AioXD3bakK7fMdhhIiouZVDB-7aebP8J1Lu1h-__g1vDz0uF_Pzrqd-leQd6Zj8_H4rOTkXW0g2EpHfb-ut_g</recordid><startdate>200902</startdate><enddate>200902</enddate><creator>Ebbens, Fenna A.</creator><creator>Georgalas, Christos</creator><creator>Luiten, Silvia</creator><creator>van Drunen, Cornelis M.</creator><creator>Badia, Lydia</creator><creator>Scadding, Glenis K.</creator><creator>Hellings, Peter W.</creator><creator>Jorissen, Mark</creator><creator>Mullol, Joaquim</creator><creator>Cardesin, Alda</creator><creator>Bachert, Claus</creator><creator>van Zele, Thibaut P. J.</creator><creator>Lund, Valerie J.</creator><creator>Fokkens, W. J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200902</creationdate><title>The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study</title><author>Ebbens, Fenna A. ; Georgalas, Christos ; Luiten, Silvia ; van Drunen, Cornelis M. ; Badia, Lydia ; Scadding, Glenis K. ; Hellings, Peter W. ; Jorissen, Mark ; Mullol, Joaquim ; Cardesin, Alda ; Bachert, Claus ; van Zele, Thibaut P. J. ; Lund, Valerie J. ; Fokkens, W. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4314-c49731229e47a524e682658361ef5523206dff450fc4cc969194f6413e2f2f093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Intranasal</topic><topic>Administration, Topical</topic><topic>Adult</topic><topic>amphotericin B</topic><topic>Amphotericin B - administration & dosage</topic><topic>Antifungal Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>chemokine CCL3</topic><topic>chemokine CCL4</topic><topic>chemokines</topic><topic>Chemokines - analysis</topic><topic>Chi-Square Distribution</topic><topic>Chronic Disease</topic><topic>cytokines</topic><topic>Cytokines - analysis</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>fungi</topic><topic>human</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Intercellular Signaling Peptides and Proteins - analysis</topic><topic>intracellular signalling peptides and proteins</topic><topic>intranasal administration</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nasal Lavage</topic><topic>nasal lavage fluid</topic><topic>nasal polyps</topic><topic>Nasal Polyps - drug therapy</topic><topic>Nasal Polyps - microbiology</topic><topic>Non tumoral diseases</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Prospective Studies</topic><topic>prospective study</topic><topic>Randomized controlled trial</topic><topic>Rhinitis - drug therapy</topic><topic>Rhinitis - immunology</topic><topic>Rhinitis - microbiology</topic><topic>rhinosinusitis</topic><topic>Sinusitis - drug therapy</topic><topic>Sinusitis - immunology</topic><topic>Sinusitis - microbiology</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebbens, Fenna A.</creatorcontrib><creatorcontrib>Georgalas, Christos</creatorcontrib><creatorcontrib>Luiten, Silvia</creatorcontrib><creatorcontrib>van Drunen, Cornelis M.</creatorcontrib><creatorcontrib>Badia, Lydia</creatorcontrib><creatorcontrib>Scadding, Glenis K.</creatorcontrib><creatorcontrib>Hellings, Peter W.</creatorcontrib><creatorcontrib>Jorissen, Mark</creatorcontrib><creatorcontrib>Mullol, Joaquim</creatorcontrib><creatorcontrib>Cardesin, Alda</creatorcontrib><creatorcontrib>Bachert, Claus</creatorcontrib><creatorcontrib>van Zele, Thibaut P. J.</creatorcontrib><creatorcontrib>Lund, Valerie J.</creatorcontrib><creatorcontrib>Fokkens, W. J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Laryngoscope</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebbens, Fenna A.</au><au>Georgalas, Christos</au><au>Luiten, Silvia</au><au>van Drunen, Cornelis M.</au><au>Badia, Lydia</au><au>Scadding, Glenis K.</au><au>Hellings, Peter W.</au><au>Jorissen, Mark</au><au>Mullol, Joaquim</au><au>Cardesin, Alda</au><au>Bachert, Claus</au><au>van Zele, Thibaut P. J.</au><au>Lund, Valerie J.</au><au>Fokkens, W. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study</atitle><jtitle>The Laryngoscope</jtitle><addtitle>The Laryngoscope</addtitle><date>2009-02</date><risdate>2009</risdate><volume>119</volume><issue>2</issue><spage>401</spage><epage>408</epage><pages>401-408</pages><issn>0023-852X</issn><eissn>1531-4995</eissn><coden>LARYA8</coden><abstract>Background:
It has been suggested that an exaggerated immune response to fungi is crucial in the pathogenesis of chronic rhinosinusitis (CRS). Based on this rationale, the use of topical antifungals (amphotericin B) has been advocated. Studies on its clinical effectiveness are, however, contradictory.
Objectives:
To examine the effect of nasal antifungal treatment on secreted mediators in samples of nasal lavage fluid from patients with CRS with or without nasal polyps (NP).
Methods:
Part two of a prospective double‐blind, placebo‐controlled multicenter clinical trial investigating the effect of 13 weeks of treatment with amphotericin B or placebo on the levels of pro‐inflammatory cytokines, chemokines and growth factors (i.e., IL‐1β, IL‐1RA, IL‐2, IL‐2R, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12 (p40/p70 subunits), IL‐13, IL‐15, IL‐17, TNF‐α, IFN‐α, IFN‐γ, G‐CSF, GM‐CSF, MIP‐1α, MIP‐1β, IP‐10, MIG, eotaxin, RANTES, MCP‐1, MCP‐2, MCP‐3, VEGF, EGF, FGF‐basic, HGF, Gro‐α) and albumin via a fluorescent enzyme immunoassay in nasal lavage specimens of CRS patients with or without NP.
Results:
Topical amphotericin B had no significant effect on the level of any of the tested pro‐inflammatory cytokines, chemokines, and growth factors in CRS nasal lavage samples. Treatment with placebo, however, increased the level of MIP‐1α and MIP‐1β, which are mediators involved in wound healing.
Conclusions:
Topical amphotericin B has no significant effect on activation markers of nasal inflammatory cells in chronic rhinosinusitis with or without nasal polyps. Laryngoscope, 2009</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19160404</pmid><doi>10.1002/lary.20064</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0023-852X |
| ispartof | The Laryngoscope, 2009-02, Vol.119 (2), p.401-408 |
| issn | 0023-852X 1531-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66878081 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Intranasal Administration, Topical Adult amphotericin B Amphotericin B - administration & dosage Antifungal Agents - administration & dosage Biological and medical sciences chemokine CCL3 chemokine CCL4 chemokines Chemokines - analysis Chi-Square Distribution Chronic Disease cytokines Cytokines - analysis Double-Blind Method Female fungi human Humans Inflammation - drug therapy Intercellular Signaling Peptides and Proteins - analysis intracellular signalling peptides and proteins intranasal administration Male Medical sciences Middle Aged Nasal Lavage nasal lavage fluid nasal polyps Nasal Polyps - drug therapy Nasal Polyps - microbiology Non tumoral diseases Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Prospective Studies prospective study Randomized controlled trial Rhinitis - drug therapy Rhinitis - immunology Rhinitis - microbiology rhinosinusitis Sinusitis - drug therapy Sinusitis - immunology Sinusitis - microbiology Statistics, Nonparametric Treatment Outcome Tumors Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| title | The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A01%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20topical%20amphotericin%20B%20on%20inflammatory%20markers%20in%20patients%20with%20chronic%20rhinosinusitis:%20A%20multicenter%20randomized%20controlled%20study&rft.jtitle=The%20Laryngoscope&rft.au=Ebbens,%20Fenna%20A.&rft.date=2009-02&rft.volume=119&rft.issue=2&rft.spage=401&rft.epage=408&rft.pages=401-408&rft.issn=0023-852X&rft.eissn=1531-4995&rft.coden=LARYA8&rft_id=info:doi/10.1002/lary.20064&rft_dat=%3Cproquest_cross%3E66878081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66878081&rft_id=info:pmid/19160404&rfr_iscdi=true |